Howard T. Holden
Plus aucun poste en cours
Profil
Howard T.
Holden held several regulatory and compliance positions in the pharmaceutical industry, including Senior Director at Parke-Davis & Co. Ltd., Vice President of Regulatory Affairs & Compliance at Ligand Pharmaceuticals, Inc., and VP of Regulatory Affairs & Quality Assurance at Array BioPharma, Inc. He also served as Chief Compliance Officer at Nventa Biopharmaceuticals Corp.
and as SVP of Regulatory & Compliance Affairs at Nereus Pharmaceuticals, Inc. Additionally, Holden worked as Vice President of Regulatory Affairs at GVIC Communications Corp.
Holden earned an undergraduate degree from Drew University and a doctorate from the University of Miami.
Anciens postes connus de Howard T. Holden
| Sociétés | Poste | Fin |
|---|---|---|
Nereus Pharmaceuticals, Inc.
 Nereus Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Nereus Pharmaceuticals, Inc. is a drug discovery and development company pursuing untapped sources of chemical diversity through identifying drug candidates derived from marine microbes. Nereus' discovery portfolio also includes additional drug candidates for oncology, inflammation, and infectious diseases. The company was founded in 1998 and is headquartered in San Diego, CA. | Compliance Officer | 01/01/2012 |
| GVIC COMMUNICATIONS CORP. | Conseiller Juridique Général | 17/10/2005 |
| ARRAY TECHNOLOGIES, INC. | Conseiller Juridique Général | - |
Parke-Davis & Co. Ltd.
 Parke-Davis & Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Parke-Davis & Co. Ltd. is a British pharmaceutical company. The company is based in St. Helier, UK. | Corporate Officer/Principal | - |
| LIGAND PHARMACEUTICALS INCORPORATED | Compliance Officer | - |
Formation de Howard T. Holden
| Drew University | Undergraduate Degree |
| University of Miami | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| Entreprise privées | 5 |
|---|---|
Nventa Biopharmaceuticals Corp.
 Nventa Biopharmaceuticals Corp. Medical SpecialtiesHealth Technology Nventa Biopharmaceuticals Corp. discovered, developed and commercialized stress protein-based therapeutic vaccines. The company was headquartered in Victoria, Canada. | Health Technology |
Nereus Pharmaceuticals, Inc.
Nereus Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Nereus Pharmaceuticals, Inc. is a drug discovery and development company pursuing untapped sources of chemical diversity through identifying drug candidates derived from marine microbes. Nereus' discovery portfolio also includes additional drug candidates for oncology, inflammation, and infectious diseases. The company was founded in 1998 and is headquartered in San Diego, CA. | Commercial Services |
Parke-Davis & Co. Ltd.
Parke-Davis & Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Parke-Davis & Co. Ltd. is a British pharmaceutical company. The company is based in St. Helier, UK. | Health Technology |
GVIC Communications Corp.
 GVIC Communications Corp. Publishing: NewspapersConsumer Services GVIC Communications Corp. operates as an information and marketing solutions company. The firm engages in the provision of information and related services through print and digital media. It operates through following segments: Environmental and Property Information, Commodity Information and Community Media. The company was founded in 1990 and is headquartered in Vancouver, Canada. | Consumer Services |
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |